SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Turboe who wrote (3336)7/17/1998 8:06:00 PM
From: Janice Shell  Read Replies (2) of 5402
 
Sanguine Corp. (OTC
BB:SGNC) and Battelle Memorial Research Institute Thursday announced that a
completed contract has been signed and that the funding is now in place for animal
testing of emulsions for use as oxygen-carrying blood substitutes.

Not to quibble, but how MUCH funding, and how long will it last?

This phrase, too, is a bit misleading:

Battelle, the world's oldest and largest independent contract research group of
scientists, engineers, and other specialists, has provided research since 1994 in
support of Sanguine's efforts to develop, manufacture and market a proprietary
synthetic red blood cell substitute.

According to the April 1998 10K, Battelle hasn't done any work at all for Sanguine SINCE 1994, when the company ran out of money.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News